Empowering Your Pipeline: Integrated Medicinal Chemistry Excellence
In drug discovery, the journey from a promising biological target to a clinical candidate is a high-stakes endeavor—one that demands precision, innovation, and a deep mastery of chemical complexity. At Oxeltis, we specialize in Medicinal Chemistry and Fine Organic Synthesis, providing the strategic expertise and technical excellence that tech transfer offices, biotechs, and mid-pharma innovators need to advance their programs with confidence.
Our approach seamlessly integrates science and strategy, ensuring your pipeline progresses efficiently through every critical milestone. From hit discovery to lead optimization, we deliver solutions that are data-driven, scalable, and aligned with your long-term goals.
01 — The first step
Hit Discovery: Precision at the Outset
The first step in drug discovery is not just about finding a hit — it's about finding the right hit. In this high-stakes phase, potential is either unlocked or lost. A poorly chosen starting point can derail even the most promising programs.
At Oxeltis, we understand that hit discovery demands a strategic blend of computational rigor and medicinal chemistry insight.
Our goal: to uncover hits that are active, scalable, synthetically accessible and aligned with your project's vision.
02 — The partnership
A Partnership for Smarter Discovery: Oxeltis & Molecular Forecaster
To redefine what’s possible in early-stage drug discovery, Oxeltis has joined forces with Molecular Forecaster, a pioneer in Computer-Aided Drug Design (CADD). Together, we don’t just identify hits—we engineer success from the very first step.
Our integrated approach addresses the most pressing challenges of hit discovery: speed, accuracy, and scalability.
01
Virtual screening at scale :
Unlocking chemical diversity
Molecular Forecaster’s state-of-the-art computational platform enables us to screen millions of compounds in silico, leveraging advanced algorithms to predict binding affinities, ADMET properties, and synthetic accessibility. By harnessing machine learning and structural bioinformatics, we rapidly narrow down vast chemical libraries to a highly curated set of candidates, each selected for its potential to become a viable hit.
02
Expert curation :
Bridging Theory and Practice
Not all computationally promising hits are created equal. Oxeltis' medicinal chemistry expertise ensures every candidate is validated, refined and prioritised:
- Synthetic feasibility:
Can the compound be efficiently synthesized at scale?
- Drug-likeness:
Does it meet the criteria for solubility, permeability, and metabolic stability?
- Developability:
Is it a strong foundation for future optimization?
This human-in-the-loop approach guarantees the hits we advance are both theoretically sound and practically viable.
03
Seamless Transition to Hit-to-Lead:
Building Momentum
Finding a hit is only the beginning. Oxeltis’ expertise in fine organic synthesis ensures that your selected hits are rapidly validated and optimized for the next phase. Our chemists work closely with your team to:
- Confirm activity through rigorous biochemical and cellular assays.
- Explore Structure-Activity Relationships (SAR) to identify the most promising chemical series.
- Lay the groundwork for lead optimization, so you can move forward with confidence.
By combining computational agility with hands-on chemical mastery, we don’t just deliver hits—we deliver a clear, actionable path forward.
Why This Partnership Works for You
In a landscape where time and precision are everything, our collaboration with Molecular Forecaster gives you a competitive edge. Whether you’re a biotech startup with limited resources or a mid-pharma company looking to de-risk your pipeline, we provide:
Faster identification of high-quality hits
Higher confidence in your early-stage candidates
A smoother transition from hit discovery to lead optimization
With Oxeltis and Molecular Forecaster, hit discovery isn’t a shot in the dark—it’s a strategic, data-driven process that sets your program up for long-term success.
FAQ - Hit Discovery Services
What is hit discovery in drug discovery?
Hit discovery is the initial phase of drug discovery where potential compounds (hits) that interact with a specific biological target are identified through various screening methods.
How does Oxeltis approach hit discovery?
Oxeltis uses an integrated approach combining computational virtual screening (in partnership with Molecular Forecaster) with expert medicinal chemistry validation to identify high-quality hits.
What makes your hit discovery process unique?
Our partnership with Molecular Forecaster allows us to screen millions of compounds in silico, while our medicinal chemistry expertise ensures hits are synthetically accessible and drug-like.
How long does the hit discovery process take?
The timeline varies depending on the target complexity, but our integrated approach typically accelerates the process by 30-40% compared to traditional methods.